Gyongyi Szabo to Endpoint Determination
This is a "connection" page, showing publications Gyongyi Szabo has written about Endpoint Determination.
Connection Strength
0.088
-
Diaz LA, Thiele M, Louvet A, Lee BP, Ajmera V, Tavaglione F, Hsu CL, Huang DQ, Pose E, Bataller R, McClain C, Mellinger J, Tincopa M, Mitchell MC, Ratziu V, Rinella ME, Sarin SK, Shah VH, Szabo G, Wong VW, Bansal MB, Leggio L, Kamath PS, Krag A, Sanyal AJ, Arrese M, Arab JP, Anstee QM, Mathurin P, Loomba R. Clinical trial design, biomarkers and end points in metabolic and alcohol-related liver disease. Nat Rev Gastroenterol Hepatol. 2025 Dec; 22(12):866-884.
Score: 0.058
-
Crabb DW, Bataller R, Chalasani NP, Kamath PS, Lucey M, Mathurin P, McClain C, McCullough A, Mitchell MC, Morgan TR, Nagy L, Radaeva S, Sanyal A, Shah V, Szabo G. Standard Definitions and Common Data Elements for Clinical Trials in Patients With Alcoholic Hepatitis: Recommendation From the NIAAA Alcoholic Hepatitis Consortia. Gastroenterology. 2016 Apr; 150(4):785-90.
Score: 0.030